Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach



Phulen Sarma1, Manisha Prajapat1, Pramod Avti2, Hardeep Kaur1, Subodh Kumar1, Bikash Medhi1

1 Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

2 Department of Biophysics, Postgraduate Institute of Medical Education and Research, Chandigarh, India





Correspondence Address:

Dr. Bikash Medhi

Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh

India

Source of Support: None, Conflict of Interest: None Check

DOI: 10.4103/ijp.IJP_119_20



1.

Graham RL, Donaldson EF, Baric RS. A decade after SARS: Strategies for controlling emerging coronaviruses. Nat Rev Microbiol 2013;11:836-48.

2.

World Health Organization. SARS (Severe Acute Respiratory Syndrome). World Health Organization. Available from: https://www.who.int/ith/diseases/sars/en/ . [Last accessed on 2020 Feb 13].

3.

Centers for Disease Control and Prevention. About MERS. Centers for Disease Control and Prevention; 2019. Available from: https://www.cdc.gov/coronavirus/mers/about/index.html . [Last accessed on 2020 Feb 13].

5.

Battegay M, Kuehl R, Tschudin-Sutter S, Hirsch HH, Widmer AF, Neher RA. 2019-novel coronavirus (2019-nCoV): Estimating the case fatality rate – A word of caution. Swiss Med Wkly 2020;150:w20203.

6.

Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses-drug discovery and therapeutic options. Nat Rev Drug Discov 2016;15:327-47.

7.

Li G, Clercq ED. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020;19:149-50.

8.

Tai DY. Pharmacologic treatment of SARS: Current knowledge and recommendations. Ann Acad Med Singapore 2007;36:438-43.

9.

Neuraminidase inhibitors for treatment of influenza A and B infections. MMWR Recomm Rep 1999;48:1-9.

10. et al. Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016. BMC Infect Dis 2018;18:331.

Bleibtreu A, Jaureguiberry S, Houhou N, Boutolleau D, Guillot H, Vallois D,. Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016. BMC Infect Dis 2018;18:331.

11. et al. Middle East respiratory syndrome coronavirus infection dynamics and antibody responses among clinically diverse patients, Saudi Arabia. Emerg Infect Dis 2019;25:753-66.

Al-Abdely HM, Midgley CM, Alkhamis AM, Abedi GR, Lu X, Binder AM,. Middle East respiratory syndrome coronavirus infection dynamics and antibody responses among clinically diverse patients, Saudi Arabia. Emerg Infect Dis 2019;25:753-66.

12. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y,. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.

13.

Dayer MR, Taleb-Gassabi S, Dayer MS. Lopinavir; a potent drug against coronavirus infection: Insight from molecular docking study. Arch Clin Infect Dis 2017;12:e13823. Available from: http://archcid.com/en/articles/13823.html . [Last accessed on 2020 Feb 12].

14.

Nukoolkarn V, Lee VS, Malaisree M, Aruksakulwong O, Hannongbua S. Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL (pro) inhibitors. J Theor Biol 2008;254:861-7.

15. et al. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax 2004;59:252-6.

Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS,. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax 2004;59:252-6.

16.

Oldfield V, Plosker GL. Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs 2006;66:1275-99.

17. et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020;7:4.

Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP,. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020;7:4.

18.

Clinical Management of Severe Acute Respiratory Infection when Novel Coronavirus (nCoV) Infection is Suspected. Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected . [Last accessed on 2020 Feb 12].

19.

Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395:473-5.

20. et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003;52:715-20.

Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W,. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003;52:715-20.

21. et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: A preliminary study. JAMA 2003;290:3222-8.

Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H,. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: A preliminary study. JAMA 2003;290:3222-8.

22.

Lau AC, Yam LY, So LK. Management of critically Ill patients with severe acute respiratory syndrome (SARS). Int J Med Sci 2004;1:1-10.

23.

Tsang K, Zhong NS. SARS: Pharmacotherapy. Respirology 2003; 8 Suppl 1:S25-30. doi: 10.1046/j.1440-1843.2003.00525.x.

24.

Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: Host-directed therapies should be an option. Lancet 2020;395:e35-6.

25. in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog 2010;6:e1001176.

te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activityand zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog 2010;6:e1001176.

28.

Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment [published online ahead of print, 2020 Feb 9]. Biosci Trends 2020;10.5582/bst.2020.01030. doi:10.5582/bst.2020.01030.

29. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507-13.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y,. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507-13.

30. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020. Available from:

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J,. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020. Available from: https://jamanetwork.com/journals/jama/fullarticle/2761044 . [Last cited on 2020 Mar 04].

31.

Zhang Z, Li X, Zhang W, Shi ZL, Zheng Z, Wang T. Clinical features and treatment of 2019-nCov pneumonia patients in Wuhan: Report of a couple cases. Virol Sin 2020. doi: 10.1007/s12250-020-00203-8.

32. et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province [published online ahead of print, 2020 Feb 7]. Chin Med J (Engl) 2020;10.1097/CM9.0000000000000744. doi:10.1097/CM9.0000000000000744.

Kui L, Fang YY, Deng Y, Liu W, Wang MF, Ma JP,. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province [published online ahead of print, 2020 Feb 7]. Chin Med J (Engl) 2020;10.1097/CM9.0000000000000744. doi:10.1097/CM9.0000000000000744.

33. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71. doi: 10.1038/s41422-020-0282-0.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M,. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV). Cell Res 2020;30:269-71. doi: 10.1038/s41422-020-0282-0.

34. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016;531:381-5.

Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V,. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016;531:381-5.

35. et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005;2:69.

Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG,. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005;2:69.

36.

Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells [Internet]. Molecular Biology; 2020. Available from: http://biorxiv.org/lookup/doi/10.1101/2020.01.31.929042 . [Last cited on 2020 Mar 04].